

**Welcome to the
PerMed Forum:**

„Personalised Medicine 2020“

at the European Health Forum Gastein

October 2nd 2014

The Coordination & Support Action (CSA) PerMed

- to step up coordination efforts between European key stakeholders
- to allow synergies and avoid duplication or competition,
- to ensure maximum transparency and openness

A consortium of **18 partners** and **9 cooperating partners**

- Research and Health Ministries, Funding Bodies,
- Research Institutes, Industry, SMEs, Foundations and Societies
- Connected to important other European initiatives related Personalized Medicine (e.g. EuroBioForum, ESF, EAPM, CASyM, 3GBTest and EPEMED)

The aims of PerMed are

- to complement existing activities by identifying and promoting promising research topics and developments,
- to prepare a **strategic research and innovation agenda (SRIA)**,
- to identify and discuss **gaps & needs** with stakeholders of all areas involved in Personalised Medicine (e.g. by workshops and interviews)
- and thereby give **strategic recommendations** how to foster the implementation of Personalised Medicine for the benefit of society.

The **Methodology** applied - 1

- Analyse around **20** strategic reports on PM to prepare an inventory of recommendations (e.g. SWOT and gaps& needs analysis)
- Develop and conduct semi-structured **interviews** with over **35** stakeholders in PM (e.g. SWOT and gaps& needs analysis)

The **Methodology** applied - 2

- **Workshops** with stakeholders to review, discuss and adapt the recommendations (March Berlin & **today**)
- Prioritise and group all input to draft a **collection** and a **short list** of the recommendations to foster PM

1. Basic Research

Re-classify diseases into “diseasomes” taking into account complex biological systems (also 2.).

Increase the understanding of genomics, transcriptomics, proteomics and metabolomics as well as the microbiome systems biology to give a more complete picture (also 2.).

Promote basic and collaborative pre-competitive, multidisciplinary and trans-disciplinary research agendas to promote translational approaches (also 2., 4. and 5.).

2. Translational and Clinical Research

Develop new and suitable models for research funding to foster personalised medicine (also 1.).

Use of analytical methods and modelling approaches to develop new models and definitions of disease (e.g. “computerized twins of patients”, also 3.).

Stimulate and support information exchange between translational research in the lab and the clinical practice to achieve an efficient Personalised Medicine (also 5.).

Enforce data harmonization and support translational research infrastructure (also 3.).

Support new methods for the pre-clinical and clinical development phase of a treatment (e.g. tools that allow translation into humans with more predictability and accuracy, also 4 and 6.).

3. Information & Communication Technology (ICT)

Develop and encourage the fast uptake of technologies for data capture, storage, management and data processing (also 2 and 5.).

Develop new decision support tools (ICT, information and communication technology) and methodologies to analyse and interpret data in order to support physicians in their decision making process (also 5.).

4. Legal Issues

Support research on the adequacy of current regulatory pathways and the development of new regulatory and legal framework for Personalized Medicine/healthcare (also 2.).

5. Health System

Promote models for the individual ownership of personal health data (also 6.).

Educate health professionals and provide funding for literacy in Personalised Medicine.

Define Personalised Medicine and provide proof of concept within the health systems (also 2.).

6. Patients

Develop communication and education strategies to increase patient and public awareness and health literacy (also 5.).

Incorporate patient participation in the healthcare ecosystem and increase their role in all phases of development (also 5.).

Today's EHFG Forum "Personalised medicine 2020"

We ask for your input and expertise!

Thank you for joining and for your kind contribution to discuss, shape and complete our recommendation on PM!